{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:44:01Z","timestamp":1788821041123,"version":"build-2803163510"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, immune checkpoint inhibitors (ICIs) have emerged as a critical component of hematological malignancies and solid malignant tumors therapy. However, clinical practice has revealed that these agents may induce immune-related adverse events (irAEs). Notably, renal irAEs stands out as a significant clinical concern, frequently necessitating treatment discontinuation and thereby enabling tumor progression. Renal irAEs constitutes a critical consideration for patients with cancer complicated by chronic kidney disease (CKD). This review systematically examines the immunologic pathogenesis of ICIs-induced renal disease, susceptibility genes, non-invasive biomarkers, and efficient intervention strategies. It further analyzes the critical considerations regarding renal irAEs that oncologists must address, based on real-world evidence from ICIs therapy in cancer patients with CKD, including those who are renal transplantation recipients or have end-stage renal disease (ESRD). Additionally, the promising targeted immunotherapy for malignant tumors is expected to improve both renal outcomes and survival prognosis in cancer patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1714090","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:51:30Z","timestamp":1770706290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Urgent considerations on renal immune-related adverse events in oncology practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Wen-Qing","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Yuan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ke","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.10.007","article-title":"Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience","volume":"174","author":"De Giglio","year":"2022","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.ajkd.2022.02.020","article-title":"Cancer risk and mortality in patients with kidney disease: A population-based cohort study","volume":"80","author":"Kitchlu","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac011","article-title":"The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes","volume":"38","author":"Lees","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272910","article-title":"Risk of Malignancy in patients with chronic kidney disease","volume":"17","author":"Tendulkar","year":"2022","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.23876\/j.krcp.18.0131","article-title":"Risk of cancer in pre-dialysis chronic kidney disease: A nationwide population-based study with a matched control group","volume":"38","author":"Park","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996\u20132009","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000508","article-title":"Assessment of GFR in patients with cancer: A statement from the american society of onco-nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and Efficacy of immune checkpoint inhibitors in patients on dialysis: A retrospective case series","volume":"76","author":"Strohbehn","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad001","article-title":"Safety of immune checkpoint inhibitors in patients with advanced chronic kidney disease: A retrospective","volume":"28","author":"Tiu","year":"2023","journal-title":"Cohort Study Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24(8)","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"2024","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.29245\/2578-2967\/2019\/4.1171","article-title":"B7 family proteins in cancer progression: immunological and non-immunological functions","author":"Ye","year":"2019","journal-title":"J Cancer Treat diagnosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eadd8947","DOI":"10.1126\/science.add8947","article-title":"Germline mutations in a G protein identify signaling cross-talk in T cells","volume":"385","author":"Ham","year":"2024","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1691608","article-title":"Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment","volume":"16","author":"Liang","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116109","article-title":"The mechanism of drug nephrotoxicity and the methods for preventing kidney damage","volume":"22","author":"Kwiatkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00278-x","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/cancers15061891","article-title":"Immune checkpoint inhibitors and the kidney: A focus on diagnosis and management for personalised medicine","volume":"15","author":"Longhitano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/jcm14093231","article-title":"Immune checkpoint inhibitor-associated acute kidney injury: A single-center experience of biopsy-proven cases","volume":"14","author":"Kommer","year":"2025","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1221135","article-title":"Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports","volume":"13","author":"Esposito","year":"2023","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","volume":"70","author":"G\u00e9rard","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12882-019-1552-2","article-title":"Ipilimumab-induced renal granulomatous arteritis: a case report","volume":"20","author":"Lemoine","year":"2019","journal-title":"BMC Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050991","article-title":"Renal sarcoidosis-like reaction induced by PD-1 inhibitor treatment in non-small cell lung cancer: A case report and literature review","volume":"59","author":"Park","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237008","article-title":"IgA nephropathy after pembrolizumab therapy for mesothelioma","volume":"13","author":"Wang","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2023.106.17","article-title":"Immune checkpoint inhibitors related cystoureteritis:A case report and literature review","volume":"26","author":"Li","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2022.2147439","article-title":"Glomerular diseases after immune checkpoint inhibitors use: What do We know so far","volume":"44","author":"He","year":"2022","journal-title":"Ren Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.34067\/kid.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney 360"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107325","article-title":"Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results","volume":"184","author":"Knox","year":"2023","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1442605","article-title":"Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review","volume":"14","author":"Gu","year":"2024","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7686","article-title":"Immune checkpoint inhibitor-induced fanconi syndrome","volume":"12","author":"Farid","year":"2020","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-025-02635-6","article-title":"Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer","volume":"29","author":"Terashita","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001463","article-title":"The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"34","author":"Guven","year":"2023","journal-title":"Anticancer Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04437-9","article-title":"Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: A meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002521","article-title":"T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab","volume":"9","author":"Hammond","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162820","article-title":"Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune-related adverse events","volume":"16","author":"Grabska","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-023-03171-9","article-title":"Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database","volume":"24","author":"Chen","year":"2023","journal-title":"BMC Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012414","article-title":"Innate and adaptive immune features associated with immune-related adverse events","volume":"13","author":"Khan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.00920121","article-title":"Gene expression profiling in kidney transplants with immune checkpoint inhibitor-associated adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12882-024-03754-0","article-title":"Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505445","article-title":"Resident macrophage-orchestrated immune and fibroblast interactions in immune checkpoint inhibitor-associated nephrotoxicity","volume":"12","author":"Ma","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010680","article-title":"Urine proteomics defines an immune checkpoint-associated nephritis signature","volume":"13","author":"Long","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010414","article-title":"Nephrotoxicity in the age of immune checkpoint inhibitors: mechanisms, diagnosis, and management","volume":"25","author":"Moturi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.06.009","article-title":"T. cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity","volume":"25","author":"Zehn","year":"2006","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.12.005","article-title":"Re-examining the nature and function of self-reactive T cells","volume":"37","author":"Richards","year":"2016","journal-title":"Trends Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: A review of the literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr Drug Saf"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand","volume":"11","author":"Franzin","year":"2020","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1014257","article-title":"Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge","volume":"9","author":"Catalano","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13054-023-04720-2","article-title":"Moving toward a contemporary classification of drug-induced kidney disease","volume":"27","author":"Karimzadeh","year":"2023","journal-title":"Crit Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.05.029","article-title":"Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis","volume":"108","author":"Gupta","year":"2025","journal-title":"Kidney Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127456","article-title":"TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132986","article-title":"Urinary cytokines reflect renal inflammation in acute tubulointerstitial nephritis: A multiplex bead-based assay assessment","volume":"10","author":"Martinez Valenzuela","year":"2021","journal-title":"J Clin Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12967-024-05177-9","article-title":"Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression","volume":"22","author":"Martinez Valenzuela","year":"2024","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf009","article-title":"CD163 detection in immune check-point inhibitors-related acute interstitial nephritis","volume":"18","author":"Perier","year":"2025","journal-title":"Clinical Kidney Journal"},{"key":"B70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clim.2019.06.005","article-title":"Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury","volume":"205","author":"Sun","year":"2019","journal-title":"Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-020-58725-w","article-title":"M2 macrophages predict worse long-term outcomes in human acute tubular necrosis","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2124678","article-title":"Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates","volume":"11","author":"Singh","year":"2022","journal-title":"Oncoimmunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae200","article-title":"Urinary soluble PD-1 as a biomarker of checkpoint inhibitor-induced acute tubulointerstitial nephritis","volume":"17","author":"Gomez-Preciado","year":"2024","journal-title":"Clin Kidney J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13243","article-title":"Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease","volume":"318","author":"Seethapathy","year":"2023","journal-title":"Immunol Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.906565","article-title":"Immunotherapy and the spectrum of kidney disease: should we individualize the treatment","volume":"9","author":"Bermejo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-4641","article-title":"Non-invasive detection of immunotherapy-induced adverse events","volume":"27","author":"Ferreira","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/jci182275","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury","volume":"134","author":"Gupta","year":"2024","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151346","article-title":"Immune checkpoint inhibitor-associated AKI: debates in diagnosis, management, and rechallenge","volume":"42","author":"Seethapathy","year":"2022","journal-title":"Semin Nephrol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115114","article-title":"PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort","volume":"213","author":"Wang","year":"2024","journal-title":"Eur J Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-0900","article-title":"Tyrosine protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma","volume":"30","author":"Monson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/genes13071204","article-title":"Severe immune-related adverse events in patients treated with nivolumab for metastatic renal cell carcinoma are associated with PDCD1 polymorphism","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Genes (Basel)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112967","article-title":"Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study","volume":"191","author":"Lumlertgul","year":"2023","journal-title":"Eur J Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215267","article-title":"Pathologic predictors of response to treatment of immune checkpoint inhibitor-induced kidney injury","volume":"14","author":"Abudayyeh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005646","article-title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","volume":"10","author":"Gupta","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241252627","article-title":"Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience","volume":"31","author":"Elghawy","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2326186","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study","volume":"46","author":"Zhou","year":"2024","journal-title":"Ren Fail"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12882-020-02226-5","article-title":"Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma","volume":"22","author":"Rassner","year":"2021","journal-title":"BMC Nephrol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae127","article-title":"Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis","volume":"17","author":"Shivaraj","year":"2024","journal-title":"Clin Kidney J"},{"key":"B94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2494433","article-title":"Impact of steroid dose and timing on efficacy of combination PD-1\/CTLA-4 blockade","volume":"14","author":"Curkovic","year":"2025","journal-title":"Oncoimmunology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae257","article-title":"Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis","volume":"40","author":"Barbir","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","volume":"10","author":"Henderson Berg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae134","article-title":"Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100309","article-title":"Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: A systematic review and meta-analysis","volume":"3","author":"Xu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000419","article-title":"Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma","volume":"8","author":"Hoffman-Censits","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071623","article-title":"Efficacy and safety of checkpoint inhibitor treatment in patients with advanced renal or urothelial cell carcinoma and concomitant chronic kidney disease: A retrospective cohort study","volume":"13","author":"Seydel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020325","article-title":"Long-term response of pembrolizumab in a patient with metastatic squamous non-small cell lung cancer on hemodialysis: case report and review of the literature","volume":"59","author":"Yun","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12663","article-title":"Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma","volume":"35","author":"Kobari","year":"2021","journal-title":"In Vivo"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"Jama"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.14570920","article-title":"De novo Malignancies after kidney transplantation","volume":"17","author":"Al-Adra","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03086-2","article-title":"Increased cancer risk in kidney transplant patients in Scotland: a national registry linkage study","volume":"133","author":"Nimmo","year":"2025","journal-title":"Br J Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015040373","article-title":"Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203352","article-title":"Epidemiological overview of colorectal cancer in kidney transplant recipients: A systematic review","volume":"17","author":"Leonforte","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000544826","article-title":"Immunotherapy and cellular therapies for cancers in kidney transplant patients","author":"Merzkani","year":"2025","journal-title":"Am J Nephrol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001851","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: A french multicenter retrospective cohort study","volume":"11","author":"Legris","year":"2025","journal-title":"Transplant Direct"},{"key":"B116","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"B117","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2374","article-title":"Outcomes of solid organ transplant recipients with advanced cancers receiving immune checkpoint inhibitors: A systematic review and individual participant data meta-analysis","volume":"11","author":"Saleem","year":"2025","journal-title":"JAMA Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14145152","article-title":"Immune checkpoint inhibitors and allograft rejection risk: emerging evidence regarding their use in kidney transplant recipients","volume":"14","author":"Khan","year":"2025","journal-title":"J Clin Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13919","article-title":"Evaluation of a decentralized donor-derived cell-free DNA assay for kidney allograft rejection monitoring","volume":"37","author":"Loupy","year":"2024","journal-title":"Transpl Int"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2014080797","article-title":"Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibody-mediated kidney allograft rejection","volume":"26","author":"Rabant","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019080847","article-title":"Terminally differentiated effector memory CD8(+) T cells identify kidney transplant recipients at high risk of graft failure","volume":"31","author":"Jacquemont","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2014040404","article-title":"Tolerant kidney transplant patients produce B cells with regulatory properties","volume":"26","author":"Chesneau","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13204","article-title":"Immunotherapy for cancer in kidney transplant patients: A difficult balance between risks and benefits","volume":"37","author":"Bolufer","year":"2024","journal-title":"Transpl Int"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001867","article-title":"Tocilizumab treatment for microvascular inflammation and chronic active antibody-mediated rejection in kidney transplantation","volume":"11","author":"Huang","year":"2025","journal-title":"Transplant Direct"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.14502","article-title":"Tocilizumab-based treatment of microvascular inflammation in kidney transplant recipients: A retrospective study","volume":"38","author":"Noble","year":"2025","journal-title":"Transpl Int"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202410340","article-title":"Engineered nanoparticles for enhanced antitumoral synergy between macrophages and T cells in the tumor microenvironment","volume":"36","author":"Moon","year":"2024","journal-title":"Adv Mater"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410545","article-title":"Co-delivery of aPD-L1 and CD73 inhibitor using calcium phosphate nanoparticles for enhanced melanoma immunotherapy with reduced toxicity","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1172\/jci139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J Clin Invest"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.04.040","article-title":"Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer","volume":"199","author":"Zhong","year":"2025","journal-title":"Acta Biomater"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003022","article-title":"Role of mitochondrial dysfunction in kidney disease: Insights from the cGAS-STING signaling pathway","volume":"137","author":"Li","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400305","article-title":"SNORD3A regulates STING transcription to promote ferroptosis in acute kidney injury","volume":"11","author":"Zhu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123396","article-title":"PD-L1 antibody-modified plant-derived nanovesicles carrying a STING agonist for the combinational immunotherapy of melanoma","volume":"322","author":"Xu","year":"2025","journal-title":"Biomaterials"},{"key":"B138","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12951-025-03129-z","article-title":"Enzymatically responsive nanocarriers targeting PD-1 and TGF-\u03b2 pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy","volume":"23","author":"Yen","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403520","article-title":"Mitochondria-targeted multifunctional nanoparticles combine cuproptosis and programmed cell death-1 downregulation for cancer immunotherapy","volume":"11","author":"Li","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B140","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.chembiol.2024.10.013","article-title":"A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden","volume":"32","author":"Rebeck","year":"2025","journal-title":"Cell Chem Biol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:20:42Z","timestamp":1771928442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2025.1714090"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1714090","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1714090"}}